BioMarck Pharmaceuticals closes on $7.5 million in new financing
Local Tech Wire
The close comes five months after the drug research firm secured two more U.S. patents. It also was awarded a $990,000 National Institutes of Health grant in February.
One new patent covers its lead compound which targets mucus in respiratory diseases. The second covers anti-inflammatory research.
BioMarck’s work forces on peptides. The patents will cover treatment of pulmonary diseases related to mucus and airway inflammation, the company said. It also is seeking international patent coverage.
The lung treatment drug, which is undergoing clinical trial, is designed to combat mucus. According to BioMarck, there are no drugs that treat pulmonary disease by targeting the excessive mucus secretion.
BioMarck licensed its technology from N.C. State,
In 2007, BioMarck secured $4 million in venture funding and won U.S. patent coverage for other key parts of its technology.
Kenneth Adler, a professor of cell biology at NCSU, made the discoveries that led to the development of BioMarck’s technology.
Please log in to view WRALTechWire Insider content
Please Log In to add a comment.
Best of TechWire Insider
- NC Biotech Center braces for worst as Senate slashes budget, too
- ArchiveSocial, a new Durham success story, brings home international award
- Durham's high-tech infrastructure, talent lure Virginia company
- Lenovo acknowledges layoffs in Morrisville as part of shift to 'PC Plus' strategy
- Raleigh-based PRA International eyes public offering
- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows